company background image
301258 logo

Suzhou Fushilai Pharmaceutical SZSE:301258 Stock Report

Last Price

CN¥24.02

Market Cap

CN¥2.2b

7D

-0.3%

1Y

-38.6%

Updated

17 Jul, 2024

Data

Company Financials

Suzhou Fushilai Pharmaceutical Co., Ltd.

SZSE:301258 Stock Report

Market Cap: CN¥2.2b

Suzhou Fushilai Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Suzhou Fushilai Pharmaceutical
Historical stock prices
Current Share PriceCN¥24.02
52 Week HighCN¥45.00
52 Week LowCN¥19.66
Beta0.39
11 Month Change-8.53%
3 Month Change-3.69%
1 Year Change-38.61%
33 Year Changen/a
5 Year Changen/a
Change since IPO-63.89%

Recent News & Updates

Suzhou Fushilai Pharmaceutical (SZSE:301258) Is Increasing Its Dividend To CN¥0.6005

Jun 07
Suzhou Fushilai Pharmaceutical (SZSE:301258) Is Increasing Its Dividend To CN¥0.6005

Recent updates

Suzhou Fushilai Pharmaceutical (SZSE:301258) Is Increasing Its Dividend To CN¥0.6005

Jun 07
Suzhou Fushilai Pharmaceutical (SZSE:301258) Is Increasing Its Dividend To CN¥0.6005

Shareholder Returns

301258CN PharmaceuticalsCN Market
7D-0.3%1.0%1.0%
1Y-38.6%-15.8%-18.1%

Return vs Industry: 301258 underperformed the CN Pharmaceuticals industry which returned -15.8% over the past year.

Return vs Market: 301258 underperformed the CN Market which returned -18.1% over the past year.

Price Volatility

Is 301258's price volatile compared to industry and market?
301258 volatility
301258 Average Weekly Movement12.4%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement6.2%
10% most volatile stocks in CN Market9.4%
10% least volatile stocks in CN Market4.1%

Stable Share Price: 301258's share price has been volatile over the past 3 months.

Volatility Over Time: 301258's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
1997544Xiangyun Qianwww.fuslai.com

Suzhou Fushilai Pharmaceutical Co., Ltd. engages in the manufacture and sale of biopharmaceutical products in China. It primarily focuses on manufacturing Alpha Lipoic Acid, L-Carnosine, and Phosphatidylcholine series of products. Its products are primarily used in medicines, dietary supplements, cosmetics, and other fields.

Suzhou Fushilai Pharmaceutical Co., Ltd. Fundamentals Summary

How do Suzhou Fushilai Pharmaceutical's earnings and revenue compare to its market cap?
301258 fundamental statistics
Market capCN¥2.20b
Earnings (TTM)CN¥66.36m
Revenue (TTM)CN¥429.09m

33.2x

P/E Ratio

5.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301258 income statement (TTM)
RevenueCN¥429.09m
Cost of RevenueCN¥291.21m
Gross ProfitCN¥137.88m
Other ExpensesCN¥71.52m
EarningsCN¥66.36m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 23, 2024

Earnings per share (EPS)0.72
Gross Margin32.13%
Net Profit Margin15.47%
Debt/Equity Ratio0%

How did 301258 perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

83%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.